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Abstract
Background
While the high burden of multidrug-resistant tuberculosis (MDR-TB) itself is a matter of
great concern, the emergence and rise of advanced forms of drug-resistance such as exten-
sively drug-resistant TB (XDR-TB) and extremely drug-resistant TB (XXDR-TB) is more
troubling. The aim of this study was to investigate the trends over time of patterns of drug re-
sistance in a sample of MDR-TB patients in greater metropolitan Mumbai, India.
Methods
This was a retrospective, observational study of drug susceptibility testing (DST) results
among MDR-TB patients from eight health care facilities in greater Mumbai between 2005
and 2013. We classified resistance patterns into four categories: MDR-TB, pre-XDR-TB,
XDR-TB and XXDR-TB.
Results
A total of 340 MDR-TB patients were included in the study. Pre-XDR-TB was the most com-
mon form of drug-resistant TB observed overall in this Mumbai population at 56.8% com-
pared to 29.4% for MDR-TB. The proportion of patients with MDR-TB was 39.4% in the
period 2005–2007 and 27.8% in 2011–2013, while the proportion of those with XDR-TB and
XXDR-TB was changed from 6.1% and 0% respectively to 10.6% and 5.6% during the
same time period. During the same periods, the proportions of patients with ofloxacin, moxi-
floxacin and ethionamide resistance significantly increased from 57.6% to 75.3%, from
60.0% to 69.5% and from 24.2% to 52.5% respectively (p<0.05).
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Discussion
The observed trends in TB drug-resistance patterns in Mumbai highlight the need for indi-
vidualized drug regimens, designed on the basis of DST results involving first- and second-
line anti-TB drugs and treatment history of the patient. A drug-resistant TB case-finding
strategy based on molecular techniques that identify only rifampicin resistance will lead to
initiation of suboptimal treatment regimens for a significant number of patients, which may
in turn contribute to amplification of resistance and transmission of strains with increasingly
advanced resistance within the community.
Introduction
India has one of the highest burdens of multidrug-resistant tuberculosis (MDR-TB) globally,
with an estimated 64,000 patients having MDR strains among notified pulmonary TB cases in
2013, which would account for more than 20 percent of the estimated global burden of drug-
resistant tuberculosis [1]. The increase in MDR-TB cases within the country has been acknowl-
edged by the Revised National Tuberculosis Control Program (RNTCP) [2] and a multi-
faceted response plan has been prepared to combat this challenge [3].
A number of studies have described the prevalence of MDR-TB in a number of different
geographical locations across the country [4–11]. The overall magnitude of the MDR-TB epi-
demic in Mumbai, one of the most known Indian mega-cities, is increasingly being docu-
mented. D’Souza et al in 2009 reported epidemic levels of drug resistance amongst new TB
cases in central Mumbai [5]. In 2011 a cases series of totally-drug resistant TB (TDR-TB) in
the city captured the attention of the medical community and the international media [12,13].
In late 2014, a survey among HIV-infected patients in the greater metropolitan Mumbai re-
ported both alarming levels of drug-resistant tuberculosis among new and previously treated
TB cases, as well as complex resistance patterns, especially high levels of resistance to fluoro-
quinolones and other second line anti-TB drugs [14]. However, as past studies have tended to
emphasize the diagnosis, treatment and care of MDR-TB, there is a dearth of literature
highlighting variations in resistance patterns over the years among selected populations.
The aim of this study was to document the patterns of drug resistance observed in MDR-TB
patients receiving anti-tuberculosis treatment in Mumbai, India and to identify the trends in
these patterns over time.
Methods
Ethics
The study was approved by the Institutional Ethics Committee of Jupiter Hospital in Mumbai,
India. As this was a retrospective analysis of routinely collected data, written informed consent
was not obtained from the study participants. The named ethics committee specifically approved
the study and waived the need for consent. Patient information was anonymized and de-identified
prior to analysis. The study also satisfied the criteria for reports using routinely collected program-
matic data set by theMédecins Sans Frontières (MSF) Ethics Review Board, Geneva, Switzerland.
Study design
The study was a retrospective, observational study using routinely collected laboratory data.
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Setting and study population
The study involved pooling data from eight medical facilities in Mumbai and the greater met-
ropolitan area: Jupiter Hospital, Bhatia Hospital, Dr. D. Y. Patil Hospital, Fortis Hospital,
L. H. Hiranandani Hospital, and Lilavati Hospital are multi-facility private hospitals in Mum-
bai and surrounding areas, each having a specialty unit for pulmonary disorders and tuberculo-
sis. The Médecins Sans Frontières (MSF) clinic is a charity-run facility located in the western
suburbs of Mumbai, which has been providing care and treatment for drug-resistant TB and
HIV free of charge since 2006. The Sewri TB hospital is a government hospital that provides
treatment to the largest cohort of MDR-TB patients in Mumbai with hospital wards designed
to accommodate tuberculosis patients.
All eight facilities included in the study were following standard international and national
guidelines on diagnosis and treatment of MDR-TB throughout the study period.
All patients enrolled in this study were suffering from bacteriologically confirmed MDR-TB
and were attending one of the eight study facilities between January 2005 and December 2013.
Tuberculosis resistance profiles
Resistance patterns were identified using drug susceptibility testing (DST). Only those patients
whose specimens where tested for both 1st and 2nd line DST at an accredited lab were consid-
ered for inclusion in the study. In the earlier years the 2nd line DST included only ofloxacin and
kanamycin; newer fluoroquinolones and injectables were added in the last years. Hinduja Hos-
pital laboratory was selected as the source of results as it is the only laboratory accredited by
the Revised National Tuberculosis Control Programme (RNTCP) in Mumbai (including ac-
creditation for 2nd line DST since December 2013); having a universal source of DST results re-
duced discrepancies in data due to multiple standards. All DST were carried out using the
MGIT 960 TB system.
A case of multidrug-resistant tuberculosis (MDR-TB) is defined as sputum/isolate in which
the culture was positive forMycobacterium tuberculosis and found to have in vitro resistance to
isoniazid and rifampicin with or without resistance to other anti-tubercular drugs based on ad-
ditional DST results.
Pre-extensively drug-resistant tuberculosis (pre-XDR-TB) patient is defined as an MDR-TB
case whose recoveredM. tuberculosis isolate is resistant to at least isoniazid, rifampicin, plus ei-
ther a fluoroquinolone (ofloxacin, levofloxacin, or moxifloxacin) or a second-line injectable
anti-TB drug (kanamycin, amikacin, or capreomycin).
Extensively drug-resistant tuberculosis (XDR-TB) patient is defined as having an MDR-TB
strain that is resistant to at least isoniazid, rifampicin, as well as any fluoroquinolone (ofloxa-
cin, levofloxacin, or moxifloxacin) and at least one second-line injectable anti-TB drug (kana-
mycin, amikacin, or capreomycin).
Extremely drug-resistant tuberculosis (XXDR-TB) patient is defined as a case of XDR-TB
with additional resistance to any group V anti-TB drugs (e.g. para-aminosalicylic acid, ethion-
amide, clofazimine, linezolid).
Management of patients diagnosed with drug-resistant TB
All patients diagnosed with MDR-TB and XDR-TB were managed in accordance with the na-
tional treatment guidelines [2], while those with pre-XDR TB and XXDR-TB (currently not in-
cluded in the national guidelines) were offered individualized treatment regimens consisting of
four anti-TB drugs likely to be effective, whenever possible.
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Data collection and statistical analysis
Clinical and laboratory data from the different facilities were pooled and merged into a single
database, which was analyzed. To improve interpretability, we collapsed the data across 3 year-
periods (2005–2007, 2008–2010, 2011–2013) to identify any periodic trends in the resistance
patterns. We also used the moving averages method to increase stability and smooth the data.
We used the Mantel-Haenszel linear-by-linear association chi-square test and Poisson re-
gression models to assess whether the changes in proportions of the different resistance pat-
terns over time were statistically significant. A p value of<0.05 was considered significant.
Data analysis was conducted with SPSS (IBM Corp. Released 2012. IBM SPSS Statistics for
Windows, Version 21.0. Armonk, NY: IBM Corp.)
Results
Patient characteristics
Reports from a total of 340 MDR-TB patients tested between January 2005 and December
2013 were included in this study. The age distribution of patients was as follows: 0–15 years 33
(9.7%), 16–25 years 109 (32.1%), 26–35 years 94 (27.6%), 36 years and above 104 (30.6%).
There were 188 males (55.3%), 150 females (44.1%) and two male-to-female transgender pa-
tients (0.6%).
Drug resistance patterns
Throughout the nine years of the study period, the proportion of study participants having
MDR-TB strains was 29.4%. Pre-XDR-TB was the most common form of drug-resistant TB in
this Mumbai population at approximately 57% of the entire cohort. The proportions of XDR-
and XXDR-TB were 9.7% and 4.1% respectively (Table 1).
Table 2 details the resistance patterns as recorded for each first and second line anti-TB
drug over time. Of note was that 235/340 (69.1%) and 179/287(62.45) of patients tested for
Ofloxacin and Moxifloxacin respectively were found to be resistant. Table 3 provides data on
the additional resistance recorded among the MDR-TB patients; 35 (10.3%) of patients had
developed resistance to 8 or more drugs, beyond the rifampicin and isoniazid while 55 (16.2%)
patients were resistant to all fluoroquinolones and injectable drugs.
Trends over time
The trends of the different forms of MDR-TB over time were not found to be statistically sig-
nificant using a Mantel-Haenszel linear-by-linear association chi-square test (for preXDR; x2 =
0.012, p = 0.91, for XXDR; x2 = 2.96, p = 0.08) and Poisson regression models. It was observed
that the proportion of patients with MDR-TB decreased from 39.4% in the period 2005–2007
to 27.8% in 2011–2013, while the proportion of patients with XDR-TB increased from 6% in
Table 1. Resistance patterns among MDR-TB patients diagnosed among 8 facilities in greater metropolitan Mumbai, 2005–2013.
Year 2005–2007 2008–2010 2011–2013 Total % Proportion among total sample
MDR 13 32 55 100 29.4%
Pre-XDR 18 64 111 193 56.8%
XDR 2 10 21 33 9.7%
XXDR — 3 11 14 4.1%
Total 33 109 198 340 100%
doi:10.1371/journal.pone.0116798.t001
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2005–2007 to 10.6% in 2011–2013 and the proportion of patients with XXDR-TB increased
from 0% in 2005–2007 to 5.5% in 2011–2013 (Fig. 1).
Moreover, the proportions of patients with additional resistance to ofloxacin, moxifloxacin
and ethionamide significantly increased over time. The linear-by-linear association chi-square-
values and p-values were x2 = 7.87, p = 0.005 for ofloxacin, x2 = 9.19, p = 0.002 for moxifloxacin
and x2 = 4.14, p = 0.04 for ethionamide (Table 2).
Discussion
To our knowledge, this is the first study of multidrug-resistant tuberculosis (MDR-TB) trends
over an extended period of time (2005–2013) in greater metropolitan Mumbai.
The six-fold increase in the absolute number of MDR-TB cases (Table 1) identified among
the eight study facilities between the first 3-year period (2005–2007) and the last 3-year period
(2011–2013), as well as the trend towards increasingly advanced patterns of resistance (i.e.
XDR- and XXDR-TB), were both most likely due in large part to improving access to 1st and
2nd-line DST. Other possible reasons include increasing awareness amongst clinicians of the
possibility of MDR-TB and the need to send specimens for DST. Regardless, these data show-
ing increasingly advanced resistance patterns represents a ‘wake up call’ to all of us working to
combat TB in Mumbai and in other parts of the country.
Just as concerning is the finding that the most common form of drug-resistant TB in this
study population was not MDR-TB but pre-XDR-TB, which is mainly due to the high levels of
baseline fluoroquinolone resistance that are present in Mumbai [14,15]. This predominance of
pre-XDR-TB has a number of important implications: firstly, the current treatment strategy
Table 2. Resistance proﬁle (ﬁrst and second-line anti-TB drugs) for MDR-TB patients in greater metropolitan Mumbai, 2005–2013.
Resistance proﬁle MDR-TB patients
2005–2007 2008–2010 2011–2013 Total
n (%) n (%) n (%) n (%)
MDR-TB patients (N) 33 109 198 340
Any resistance to ﬁrst-line drugs
S 27 (81.8) 96 (88.1) 179 (90.4) 302 (88.8)
H 32 (97.1) 108 (99.1) 197 (99.5) 337 (99.1)
R 33 (100) 109 (100) 198 (100) 340 (100)
E (N = 339) 22 (66.7) 78 (72.2) 156 (78.8) 256 (75.5)
Z (N = 309) 10 (43.5) 71 (76.3) 158 (81.9) 239 (77.3)
Any resistance to second-line drugs
Ofx 19 (57.6) 67 (61.5) 149 (75.3) 235 (69.1)*
Mfx (N = 287) 6 (60.0) 41 (47.1) 132 (69.5) 179 (62.4)*
Am (N = 292) - 12 (13.0) 29 (15.3) 41 (14.0)
Cm - 10 (11.5) 25 (13.2) 35 (12.4)
Km (N = 339) 4 (12.5) 17 (15.6) 35 (17.7) 56 (16.5)
Eto 8 (24.2) 60 (55.0) 104 (52.5) 172 (50.6)*
Cfz (N = 282) - 2 (2.4) 3 (1.6) 5 (1.8)
PAS (N = 339) 8 (25.0) 28 (25.7) 48 (24.2) 84 (24.8)
S-streptomycin, H-isoniazid, R-rifampicin, E-ethambutol, Z-Pyrazinamide, Ofx-oﬂoxacin, Mfx-Moxiﬂoxacin, Km-kanamycin, Am-Amikacin, Cm-
capreomycin, Eto-ethionamide, Cfz-Clofazimine, PAS-para-aminosalicylic acid
*Linear-by-linear association chi-square test, p value<0.05.
doi:10.1371/journal.pone.0116798.t002
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that relies on standardized regimens to treat a traditional classification of MDR-TB carries a
high risk of being suboptimal treatment. In many cases, a standardized MDR-TB regimen will
not contain ‘four drugs likely to be effective’, as recommended by the WHO, if prescribed to a
person with disease due to a pre-XDR-TB strain [16]. Not only does a suboptimal treatment
regimen reduce the likelihood of a cure, but it can also lead to amplification of drug resistance,
such that the pre-XDR-TB strain becomes an XDR-TB strain, which in turn can be transmitted
within the household and community.
Secondly, all patients at risk of suffering from active TB disease due to a drug-resistant strain
need to have drug susceptibility testing (DST) performed not just against first-line anti-TB
drugs, but also against flouroquinolones and other second-line anti-TB drugs during the initial
work-up. The current trend in India is to move towards routine use of a molecular TB diagnos-
tic, for example Xpert MTB/RIF (also known as GeneXpert), which can rapidly detect rifampi-
cin resistant strains of Mycobacterium tuberculosis within 2 hours. Although this can be
viewed as an important step forward, it should be acknowledged that use of GeneXpert in set-
tings like Mumbai may contribute to suboptimal prescribing practices, since detection of rifam-
picin resistance alone may mask a diagnosis of pre-XDR or XDR-TB (or worse). In settings like
Mumbai, GeneXpert alone will not control the MDR-TB epidemic: TB culture and full DST
must accompany its implementation. This will require an increasing state and government in-
vestment in laboratory capacity in order to meet the needs of TB patients and clinicians.
Thirdly, inappropriate prescribing patterns related to active TB disease in the private health
sector and easy/over-the-counter access to fluoroquinolones both need to be halted as soon as
possible. Although high levels of amplification of drug resistance have been demonstrated
Table 3. Additional resistance to ﬁrst and second-line anti-TB drugs among MDR-TB patients in
greater metropolitan Mumbai, 2005–2013.
Resistance proﬁle MDR-TB patients (N = 340)
n (%)
Number of additional anti-TB drugs to which MDR-TB patients were
resistant
0* 8 (2.4)
1 22 (6.5)
2 35 (10.3)
3 50 (14.7)
4 59 (17.4)
5 62 (18.2)
6 42 (12.4)
7 27 (7.9)
8 and above 35 (10.3)
Additional second line anti-TB drugs to which MDR-TB patients were
resistant
Ofx 89 (26.2)
Km 3 (0.9)
Eto 25 (7.6)
Ofx+Eto 99 (29.1)
Km+Eto 5 (1.5)
Ofx/Mfx+Km/Am/Cm 55 (16.2)
* Resistance to rifampicin and isoniazid only, Ofx-oﬂoxacin, Mfx-Moxiﬂoxacin, Km-kanamycin, Am-
Amikacin, Cm-capreomycin, Eto-ethionamide.
doi:10.1371/journal.pone.0116798.t003
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under well-established DOTS programme conditions [17], additional factors are contributing
to the MDR-TB situation in Mumbai, namely a chaotic and unregulated private health sector
that operates in parallel with the public DOTS programme, in which suboptimal TB treatment
regimens are commonly being prescribed [18–20].
The results we have observed are in a sample population spread out over the cities of Mum-
bai, Navi Mumbai and Thane. Given the high population density in these settings, where a
large proportion of the population lives in extreme poverty in slums, these data are unlikely to
be representative of the state of Maharashtra and even less likely of the whole of India. Howev-
er, the living conditions in Mumbai and the common practices in the private health sector (i.e.
the prescribing of inappropriate TB treatment regimens and over-the-counter availability of
fluoroquinolones and other drugs having anti-TB properties) are similar to those of other large
metropolitan centres in the country.
This study is subject to the usual limitations inherent with retrospective design and data col-
lection. Our sample size is small and may be not fully representative of the population of DR-
TB patients within the setting. The extremely limited laboratory capacity in Mumbai prevented
us from having a larger sample; until 2011 there was only one accredited laboratory in Mumbai
for DST to first-line anti-TB drugs (which was private) and until December 2013 there was no
accredited laboratory for DST to second-line drugs. Moreover we believe that there were sever-
al cases of MDR-TB cases that did not undergo 2nd line DST, as the cost had to be covered by
the patients themselves, and therefore the representativeness of our study may be further limit-
ed. We feel that the numbers of cultures and tests performed during the study period were
abysmal, considering the size of the population and the magnitude of the MDR-TB epidemic
in Mumbai. As the study was limited to bacteriologically confirmed patients, specific popula-
tions, especially small children and HIV-infected patients with culture negative tuberculosis
might have been underrepresented in this study. The lack of statistical significance in the trends
Figure 1. Trends over time of resistance patterns among DR-TB patients diagnosed in 8 facilities in greater metropolitan Mumbai, 2005–2013
doi:10.1371/journal.pone.0116798.g001
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analysis can be attributed to the small sample size; we believe that the descriptive statistics illus-
trate the trends over time in drug resistance patterns but they should be interpreted with cau-
tion. We were not able to analyze patient characteristics even though we had access to
individual patient data rather than aggregated data. However, we had access to limited demo-
graphic and clinical data of individual patients. We were also not able to ascertain whether
some patients were tested more than once during the study period. However, considering the
small size of the cohort in each facility, individual patients were easily identifiable by the treat-
ing physicians who kept their records up-to-date and therefore double entries were rather un-
common. Last, we had no access to fingerprinting data for this population, which could have
complemented our description of the circulating strains. Despite these limitations we believe
that our study adds important data and insights into the description of the drug-resistant tu-
berculosis epidemic in metropolitan Mumbai.
We emphasize the importance of developing a robust surveillance system for drug resistance
in the city and the country rather than depending on infrequent national and limited sub-na-
tional surveys. National surveys albeit scientifically acceptable, they may mask significant vari-
ance in the magnitude of the epidemic in various localities areas or specific populations. This is
especially relevant for vast countries like India and mega-cities like Mumbai where several
drug-resistant TB epidemics may exist.
Ongoing research is necessary to provide an evidence base for appropriate public health ac-
tion. Use of targeted molecular-guided cluster analyses should be considered in order to identi-
fy patterns of transmission at the population level. In the face of growing proportions of pre-
XDR-TB, XDR- and XXDR-TB, these efforts must be initiated promptly. Official recognition
and categorization of TB strains that are resistant to three or more anti-TB drugs (e.g. pre-
XDR-TB) are needed, not only to standardize research efforts, but also to help ensure that
these patients receive appropriate treatment regimens.
Conclusion
The observed trends in TB drug resistance patterns in metropolitan Mumbai highlight the
need for individualized drug regimens, designed on the basis of full drug susceptibility results
to first- and second-line anti-TB drugs. A drug-resistant TB case-finding strategy, based solely
on rapid molecular techniques such as GeneXpert that identify only TB with Rifampicin resis-
tance, may contribute to suboptimal treatment regimens for the many patients suffering from
disease due to pre-XDR-TB strains, and may lead to amplification resistance and spread of fur-
ther worse forms of drug-resistant TB within the community.
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